CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 59 enrolled
Drug / intervention
Selinexor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02323880
NCT02323880Phase 1Completed
CompareCT.gov

A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Children's Oncology Group·interventional·Posted Dec 24, 2014·Updated Jan 14, 2025

In Brief

A Phase 1 clinical trial evaluating Pharmacological Study and Selinexor for Malignant Glioma and 9 related conditions. Completed, enrolled 59 participants across 23 sites.

Detailed Summary

This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 24, 2014
Enrollment StartOct 30, 2015
Primary CompletionSep 30, 2022
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 11.5 years ago

Interventions

Pharmacological Studyother

Correlative studies

Selinexordrug

Given PO